Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

(NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical ... Doxorubicin, approved almost 50 years ago, remains the recommended 1st line systemic treatment despite exhibiting minimal ...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...

Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate ...

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing ...

Investopedia / Zoe Hansen Money line bets are wagers placed on a game’s outcome. In essence, they are bets on which team or competitor will win any given match. As the wager is on who will win ...

According to Dr. Steven D. Reich, Senior VP of Clinical Development and Acting Chief Medical Officer at Actuate, the current first-line systemic treatment for metastatic STS is doxorubicin ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Actuate Therapeutics has won Food and Drug Administration orphan-drug designation for its lead investigational drug product in a group of rare cancerous tumors. Actuate on Wednesday said the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...